Ticker

Connor Clark and Lunn Investment Management Ltd. purchased a new position in Quest Diagnostics Incorporated (NYSE: DGX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 3,113 shares of the medical research company's stock, valued at approximately $660,000. Other

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Bank OZK purchased a new position in Quest Diagnostics Incorporated (NYSE: DGX) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 15,322 shares of the medical research company's stock, valued at approximately $3,247,000. Other institutional investors and hedge funds have also made changes to their

Artia Global Partners LP purchased a new stake in shares of Quest Diagnostics Incorporated (NYSE: DGX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 65,122 shares of the medical research company's stock, valued at approximately $13,803,000. Quest Diagnostics

SECAUCUS, N.J., Aug. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026, at 10:50 a.m.